ストックスクリーナーアプリを入手
0.7646
4.02%
0.0296
アフターアワーズ：
.76
-0.00455
-0.60%
Avenue Therapeutics Inc (ATXI) 最新ニュース
Avenue Therapeutics Leads Six-Month Stock Performance with 267.29% Return - Markets Mojo
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - Stocktwits
Avenue Therapeutics Leads Six-Month Stock Performance with 253.98% Return - Markets Mojo
Avenue Therapeutics Leads Six-Month Stock Performance with 257.7% Return - Markets Mojo
Avenue Therapeutics Inc. (ATXI) Stock Price | Live Quotes & Charts | OTO - StocksToTrade
Village Farms International Leads with 276.7% Return in Recent Six Months - Markets Mojo
Avenue Therapeutics Announces 2025 Annual Meeting Date - The Globe and Mail
[8-K] AVENUE THERAPEUTICS, INC. Reports Material Event | ATXI SEC FilingForm 8-K - Stock Titan
Village Farms International Leads with 282% Return in Recent Performance Surge - Markets Mojo
Village Farms International Leads with 275% Return in Recent Performance Surge - Markets Mojo
Axsome Therapeutics stock hits all-time high at 144.19 USD By Investing.com - Investing.com Nigeria
Avenue Therapeutics Leads Six-Month Stock Performance with 333.85% Return - Markets Mojo
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Avenue Therapeutics Reports Improved Financials Amid Challenges - TipRanks
Avenue Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Village Farms International Leads Six-Month Stock Performance with 424.66% Return - Markets Mojo
Avenue Therapeutics Sells Baergic Bio to Axsome - TipRanks
ATXI SEC FilingsAvenue Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
Village Farms International Leads with 418.66% Return in Recent Performance - Markets Mojo
Village Farms International Leads with 354.34% Return in Recent Performance - Markets Mojo
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - MSN
Axsome Therapeutics Eyes Baergic Bio: Is This the Next Big CNS Breakthrough? - Smartkarma
Axsome Therapeutics Buys Global Rights To AZD7325 To Expand Epilepsy Pipeline - Pulse 2.0
Deutsche Bank Sticks to Its Sell Rating for AstraZeneca (AZN) - The Globe and Mail
Nebius Group NV Leads Six-Month Stock Performance with 359.83% Return - Markets Mojo
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate By Investing.com - Investing.com Australia
Avenue shares rights to epilepsy drug candidate with Axsome in deal - Investing.com Nigeria
Axsome acquires global rights to AstraZeneca’s epilepsy drug candidate - Investing.com India
Axsome Therapeutics stock hits all-time high at 139.22 USD By Investing.com - Investing.com South Africa
Axsome Therapeutics stock hits all-time high at 139.22 USD - Investing.com India
Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus
AZN Secures Deal with Axsome for Epilepsy Drug Development - GuruFocus
Avenue shares rights to epilepsy drug candidate with Axsome in deal By Investing.com - Investing.com South Africa
Axsome Therapeutics IncObtains Exclusive G - 富途牛牛
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - The Manila Times
OTC Markets Group Welcomes SUN SILVER LTD. to OTCQX - The Manila Times
Axsome Therapeutics, Inc. entered into an agreement to acquire Baergic Bio, Inc. from Avenue Therapeutics, Inc. for $79.3 million. - MarketScreener
Global Pain Management Devices Market Set to Expand Rapidly at a CAGR of ~8% by 2032 Amid Growing Preference for Minimally Invasive Solutions | DelveInsight - Business Upturn
Nebius Group NV Leads Six-Month Stock Performance with 374.29% Return - Markets Mojo
OVID PRE 14A: approvals for Series B conversion and warrants - Stock Titan
Can Dianthus Therapeutics Inc. stock attract ESG capital inflowsPortfolio Value Summary & AI Driven Price Forecasts - fcp.pa.gov.br
Lirum Therapeutics Announces FDA 'Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor - The Manila Times
Lirum Therapeutics Announces FDA “Study May Proceed” Letter - GlobeNewswire
Head to Head Survey: Avenue Therapeutics (NASDAQ:ATXI) vs. Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - The Manila Times
0.45%
1.13%
大文字化:
|
ボリューム (24 時間):